Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1356
Abstract: Both the combination of nivolumab + ipilimumab and single‐agent anti‐PD‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized… read more here.
Keywords: combination; immunotherapy; combination nivolumab; clinical laboratory ... See more keywords
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33328
Abstract: In this multicenter, single‐arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder and upper tract carcinoma of variant histology (BUTCVH), adrenal tumors,… read more here.
Keywords: phase; histology; advanced rare; patients advanced ... See more keywords
The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions
Sign Up to like & getrecommendations! Published in 2019 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-019-0638-1
Abstract: Opinion statementFor the practicing clinician, the dilemma becomes how most appropriate to sequence the aforementioned regimens. It is challenging to be dogmatic, as there are no comparative studies juxtaposing novel front-line options directly—all of the… read more here.
Keywords: treatment; disease; risk disease; good risk ... See more keywords
Facteurs pronostiques et prédictifs associés au traitement par nivolumab et ipilimumab chez les patients présentant un mélanome métastatique
Sign Up to like & getrecommendations! Published in 2020 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2020.09.083
Abstract: Introduction L’association nivolumab et ipilimumab (NIVO + IPI) a considerablement ameliore le pronostic des patients avec melanome metastatique, en particulier en cas de metastases cerebrales. Neanmoins, elle est responsable d’effets indesirables severes dans environ 55 % des cas.… read more here.
Keywords: chez les; les patients; nivo ipi; metastases cerebrales ... See more keywords
Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2020.10.004
Abstract: Nivolumab-ipilimumab has become the standard of care in the frontline setting for intermediate-/poor-risk metastatic renal cell carcinoma (mRCC). This regimen is associated with survival improvement but significant toxicity. Anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)… read more here.
Keywords: renal cell; analysis; ipilimumab; prior anti ... See more keywords
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.11.031
Abstract: BACKGROUND Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for naïve patients with intermediate or poor risk prognosis (International… read more here.
Keywords: renal cell; line; ipilimumab failure; metastatic renal ... See more keywords
Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2022.2116845
Abstract: ABSTRACT Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in mUM.… read more here.
Keywords: metastatic uveal; combination; retrospective cohort; nivolumab ipilimumab ... See more keywords
Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djad003
Abstract: BACKGROUND An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality-of-life (QOL). We compared QOL in patients enrolled to SWOG-1400I, a substudy… read more here.
Keywords: ipilimumab nivolumab; risk; nivolumab ipilimumab; quality life ... See more keywords
Drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Dermatology"
DOI: 10.1111/pde.14940
Abstract: Drug‐induced hypersensitivity syndrome (DIHS) is a type of severe cutaneous adverse reaction (SCAR). DIHS typically occurs 2–6 weeks after initiation of the offending medication. We report a case of DIHS in a pediatric patient undergoing… read more here.
Keywords: drug induced; hypersensitivity syndrome; pediatric patient; drug ... See more keywords
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004273
Abstract: Background Retrospective studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors (ICIs). We compared the incidence of HPD during treatment with nivolumab±ipilimumab versus natural tumor progression with placebo… read more here.
Keywords: placebo; versus placebo; ipilimumab versus; nivolumab ipilimumab ... See more keywords
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004780
Abstract: Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to initial nivolumab… read more here.
Keywords: cell; salvage nivolumab; treatment; histology ... See more keywords